GI Practices Lose More on Second Procedures Than Any Other Specialty, Jiro Health Benchmark Finds

Jiro Health’s 2026 gastroenterology benchmark found that 20.7% of paid second procedures receive less than 25% of their standard rate; gastroenterologists typically receive about 32%–38% of that rate, and 28.4% of GI visits include multiple procedures. The analysis estimated a paid-claims shortfall of about $5,894 per physician annually versus larger local independent practices, or $17,681 for a representative three-physician practice, while cautioning that these estimates are floors, not guaranteed recoveries.

Analysis

The key economic implication is not simply lower GI reimbursement: it is that the marginal procedure in a multi-procedure visit may contribute far less revenue than its standalone rate suggests. That weakens the payoff to adding procedural capacity unless practices can improve scheduling density, negotiate contract language, or document separately payable work. Because the benchmark says much of the reduction reflects same-scope rules, treating every low payment as recoverable underpayment risks overstating near-term revenue upside.

Over 1–3 months, the likely response is more contract-level auditing and negotiation, but the reported scale premium does not establish that any individual practice can capture it; the study is observational, and its estimated shortfall is explicitly incomplete. Over 6–18 months, persistent pressure could strengthen incentives for independent groups to join larger platforms, where contracting scale may help—but integration costs and payer mix determine whether that translates into better margins. A shift toward facility-based settings is not an automatic beneficiary: the analysis excludes facility fees, so it does not establish a net site-of-care advantage.

The contrarian point is that the headline rate reductions may look more alarming than their incremental economic impact if they mostly reflect established payment policy rather than newly imposed cuts. Conversely, the scale effect may matter more than the benchmark’s per-physician estimate if it compounds across a large platform. No public pure-play GI exposure is identified here, and the data do not support a directional trade in hospital or device stocks.

Key Decisions for Investors

• No immediate sector trade: the release is a claims benchmark, not evidence of a new payer-policy change or a quantified earnings revision for a public company.
• For diligence on GI practice platforms, track same-session procedure mix, realized collections per visit, contract-level allowed amounts, denial/appeal recovery, and physician retention before underwriting scale-related reimbursement gains.
• Treat contract renegotiation as a 1–3 month catalyst only where practices can show payer-specific payment variance beyond correctly applied same-scope reductions; verify against remits and contract terms rather than the benchmark alone.
• Watch for independent-group consolidation over 6–18 months. The thesis weakens if larger groups fail to demonstrate better realized collections after adjusting for payer, geography, care setting, and procedure mix.